{"entity":{"id":"nct03268382","kind":"trial","name":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","aka":["PiSARRO-R"],"tldr":"A phase 2 trial of Eprenetapopt and Pegylated liposomal doxorubicin in Ovarian cancer, run by Aprea Therapeutics, completed.","summary":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 is a phase 2 interventional study registered as NCT03268382 by Aprea Therapeutics, with 36 participants recorded, started 2017-07-31 and reaching its primary completion in 2019-07-10. Interventions recorded: APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD). Conditions recorded: High-grade Serous Ovarian Cancer.\n\nLinked to the idea \"Is aneuploidy itself a druggable vulnerability?\" because the registry names Eprenetapopt and Pegylated liposomal doxorubicin among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03268382","url":"https://clinicaltrials.gov/study/NCT03268382"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","high-grade-serous-ovarian-cancer","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["eprenetapopt","pegylated-liposomal-doxorubicin"],"companies":["aprea-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03268382","phase":"2","setting":"PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246","sponsor":"Aprea Therapeutics","started":"2017-07-31","startedType":"actual","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03268382/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"}],"company":[{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","route":"/companies/aprea-therapeutics/"}],"idea":[{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/"}]}}